GlassScriptPhysician profile
Ivan J Gamboa
NPI 1366739468
$24,746.48
in general payments reported to CMS, 2019-2025
64 companies · $4,220 in 2025
The $4,220 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,381 · 2020: $3,350 · 2021: $3,399 · 2022: $3,947 · 2023: $3,198 · 2024: $4,252 · 2025: $4,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $36.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,633.14 |
| Education | $36.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,374.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,773.83 | 2019-2025 | Mounjaro, Zepbound, Humulin |
| Abbott Laboratories | $1,467.11 | 2019-2025 | Freestyle Libre 3, Freestyle Libre |
| Medtronic Minimed, INC. | $1,428.54 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $1,267.46 | 2019-2023 | Farxiga |
| Dexcom, INC. | $1,218.08 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,215.48 | 2019-2023 | Cycloset |
| Amgen INC. | $1,114.50 | 2019-2025 | Tepezza, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $1,020.42 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $901.29 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $895.93 | 2019-2025 | Jardiance, Trijardy Xr, Synjardy |
| Corcept Therapeutics | $868.31 | 2019-2025 | Korlym |
| Medtronic, INC. | $744.53 | 2021-2025 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Radius Health, INC. | $706.72 | 2019-2025 | Tymlos |
| Insulet Corporation | $661.40 | 2019-2025 | Omnipod |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $447.14 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $447.00 | 2021-2025 | |
| Antares Pharma, INC. | $394.34 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Merck Sharp & Dohme LLC | $372.65 | 2019-2023 | Steglatro |
| Novartis Pharmaceuticals Corporation | $320.06 | 2022-2025 | Leqvio |
| Ibsa Pharma INC. | $318.80 | 2019-2025 | Licart, Tirosint, Flector |
| Amneal Pharmaceuticals LLC | $286.39 | 2019-2024 | Unithroid |
| Beta Bionics, INC. | $249.03 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amarin Pharma, INC. | $231.48 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $213.53 | 2024-2025 | Yorvipath |
| Nevro Corp. | $193.27 | 2023 | Senza |
| Mannkind Corporation | $188.67 | 2020-2024 | |
| Becton, Dickinson and Company | $182.67 | 2019-2022 | |
| Tolmar, INC. | $171.50 | 2024-2025 | Jatenzo |
| Kowa Pharmaceuticals America, INC. | $169.16 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $156.64 | 2020-2025 | Isturisa, Signifor Lar |
| Kyowa Kirin, INC. | $155.54 | 2023-2025 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $134.92 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $134.45 | 2024-2025 | |
| Horizon Therapeutics Plc | $126.59 | 2022-2023 | Tepezza |
| Alexion Pharmaceuticals, INC. | $125.26 | 2019-2024 | Strensiq |
| Sequel Med Tech, LLC | $106.45 | 2025 | Twiist |
| Kvk-Tech, INC. | $102.70 | 2019 | |
| Pfizer INC. | $96.10 | 2023-2024 | |
| Chiesi USA, INC. | $68.44 | 2024-2025 | Mycapssa |
| Globus Medical, INC. | $61.97 | 2025 | Senza |
| Shire North American Group INC | $48.36 | 2019 | |
| Ucb, INC. | $47.70 | 2025 | Briviact |
| Amryt Pharma Holdings LTD | $42.13 | 2020-2022 | |
| Lundbeck LLC | $40.73 | 2025 | Rexulti, Vyepti |
| Madrigal Pharmaceuticals | $39.34 | 2025 | Rezdiffra |
| Companion Medical, INC. | $33.96 | 2019-2020 | |
| Cequr Corporation | $31.23 | 2024-2025 | Cequr Simplicity |
| Clarus Therapeutics INC. | $29.84 | 2021 | |
| Biotronik Nro, INC. | $28.68 | 2025 | Prospera |
| Acerus Pharmaceuticals Corporation | $28.30 | 2022 | |
| Endo Pharmaceuticals INC. | $28.05 | 2019-2021 | |
| Genentech USA, INC. | $25.67 | 2025 | Ocrevus Zunovo |
| Almatica Pharma LLC | $25.28 | 2024 | Teriparatide, Loreev Xr |
| Biogen, INC. | $23.63 | 2024 | Tysabri, Vumerity |
| Rhythm Pharmaceuticals, INC. | $22.83 | 2025 | Imcivree |
| Halozyme INC | $20.48 | 2023 | |
| Averitas Pharma INC. | $20.08 | 2025 | Qutenza |
| Zealand Pharma US, INC. | $20.03 | 2022 | |
| Soleno Therapeutics, INC. | $17.97 | 2025 | Vykat Xr |
| Acella Pharmaceuticals, LLC | $17.66 | 2025 | NP Thyroid 60 |
| Teva Pharmaceuticals USA, INC. | $16.04 | 2025 | Austedo Xr |
| Amphastar Pharmaceuticals, INC. | $13.13 | 2024 | Baqsimi |
| Janssen Pharmaceuticals, INC | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Gamboa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.